Using scandium chemistry to create new radiopharmaceuticals for imaging and therapy
Harnessing scandium chelation chemistry for the development of radiopharmaceuticals
This study is working on new types of medical imaging and treatment using a special metal called scandium, which could help doctors see and treat diseases more accurately, making it easier for patients to get the care they need.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11118818 on NIH RePORTER |
What this research studies
This research focuses on developing new radiopharmaceuticals using scandium, a metallic radioisotope, to improve diagnostic imaging and therapeutic applications in nuclear medicine. By enhancing the production of radiometals and understanding their aqueous chemistry, the project aims to create radiopharmaceuticals that can provide better imaging and treatment options for various diseases. The study will explore the properties of scandium isotopes, which have ideal characteristics for positron emission tomography (PET) imaging and therapeutic use. Patients may benefit from more accurate diagnostics and targeted therapies as a result of this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients requiring advanced imaging techniques or targeted radiotherapy for their conditions.
Not a fit: Patients who do not require imaging or radiotherapy, or those with conditions not addressed by this research, may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective imaging and treatment options for patients with various diseases.
How similar studies have performed: Other research has shown promise in using metallic radioisotopes for imaging and therapy, indicating that this approach has potential for success.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Boros, Eszter — University of Wisconsin-Madison
- Study coordinator: Boros, Eszter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.